Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.42 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 5/20 | 0.39 |
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
| ▸ | HTR2B | P41595 | 3/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | GCK | P35557 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2658113 | 0.81 | S1PR4 (0.38) | GRM2TGFBR1GCK | |
| SCHEMBL2656458 | 0.80 | GAA (0.32) | SLC22A12 | |
| SCHEMBL2660556 | 0.79 | GCK (0.38) | SLC22A12CCR2HTR2CHTR2AHTR2B | |
| SCHEMBL2657140 | 0.79 | MAP4K4 (0.44) | SLC22A12CCR2HTR2CHTR2AHTR2B | |
| SCHEMBL2657273 | 0.79 | GCK (0.46) | SLC22A12CCR2ADORA2AADORA1GCK | |
| SCHEMBL2661543 | 0.77 | GCK (0.42) | SLC22A12CCR2GRM2GCK | |
| SCHEMBL2655935 | 0.77 | GCK (0.59) | GCK | |
| SCHEMBL15404185 | 0.74 | SLC22A12 (0.43) | SLC22A12MAP4K4 | |
| SCHEMBL2656340 | 0.74 | L3MBTL1 (0.39) | SLC22A12 | |
| SCHEMBL2654892 | 0.74 | SMN1; SMN2 (0.43) | HTR2CHTR2AHTR2BGCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3078662-A1 | PYRIDIN-2-YL-AMINO-1,2,4-THIADIAZOLE DERIVATIVES AS GLUCOKINASE ACTIVATORS FOR THE TREATMENT OF DIABETES MELLITUS | Array Biopharma, Inc. (US) | 2016-10-12 | — | — | EP | disclosed |
| EP-2727910-B1 | Pyridin-2-yl-thiourea and Pyridin-2-yl-amine derivatives as intermediates for the preparation of Pyridin-2yl-amino-1,2,4-thiadiazole glucokinase activators | ARRAY BIOPHARMA INC (US) | 2016-03-16 | — | — | EP | disclosed |
| US-20150299182-A1 | CRYSTALLINE FORMS OF (1S)-1-[5-(AMINO)-1,2,4-THIADIAZOL-3-YL]ETHANE-1,2-DIOL | AMGEN INC. (US) | 2015-10-22 | — | — | US | disclosed |
| US-9079890-B2 | Intermediates for the preparation of pyridin-2-yl-amino-1,2,4-thiadiazole derivatives | ARRAY BIOPHARMA INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20150057448-A1 | INTERMEDIATES FOR THE PREPARATION OF PYRIDIN-2-YL-AMINO-1,2,4-THIADIAZOLE DERIVATIVES | ARRAY BIOPHARMA, INC. | 2015-02-26 | — | — | US | disclosed |
| US-8853409-B2 | Pyridin-2yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus | ARRAY BIOPHARMA INC. (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2727910-A1 | Pyridin-2-yl-thiourea and Pyridin-2-yl-amine derivatives as intermediates for the preparation of Pyridin-2yl-amino-1,2,4-thiadiazole glucokinase activators | Array Biopharma, Inc. (US) | 2014-05-07 | — | — | EP | disclosed |
| EP-2573087-A1 | Pyridin-2-yl-amino-1,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus | Array Biopharma, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| US-8362037-B2 | 2-aminopyridine analogs as glucokinase activators | ARRAY BIOPHARMA, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120277242-A1 | Pyridin-2YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus | ARRAY BIOPHARMA, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| EP-2209778-B1 | PYRIDIN-2 -YL-AMINO-I, 2, 4 -THIADIAZOLE DERIVATIVES AS GLUCOKINASE ACTIVATORS FOR THE TREATMENT OF DIABETES MELLITUS | ARRAY BIOPHARMA INC (US) | 2012-08-29 | — | — | EP | disclosed |
| US-8212045-B2 | Pyridin-2-yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus | ARRAY BIOPHARMA, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20100204240-A1 | Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus | ARRAY BIOPHARMA INC. (US) | 2010-08-12 | — | — | US | disclosed |
| EP-2209778-A1 | PYRIDIN-2 -YL-AMINO-I, 2, 4 -THIADIAZOLE DERIVATIVES AS GLUCOKINASE ACTIVATORS FOR THE TREATMENT OF DIABETES MELLITUS | Array Biopharma, Inc. (US) | 2010-07-28 | — | — | EP | disclosed |
| US-20100105659-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPPHARMA INC. (US) | 2010-04-29 | — | — | US | disclosed |
| EP-2173745-A2 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | Array Biopharma, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009042435-A1 | PYRIDIN-2 -YL-AMINO-I, 2, 4 -THIADIAZOLE DERIVATIVES AS GLUCOKINASE ACTIVATORS FOR THE TREATMENT OF DIABETES MELLITUS | ARRAY BIOPHARMA INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| WO-2008118718-A2 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299182-A1 | CRYSTALLINE FORMS OF (1S)-1-[5-(AMINO)-1,2,4-THIADIAZOL-3-YL]ETHANE-1,2-DIOL | SLC5A1, IAPP, PTGER1 | SLC22A12 4041/4885CCR2 2056/4885HTR2C 272/4885 |
| US-20120277242-A1 | Pyridin-2YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus | PDXK, GCKR, GCK | SLC22A12 3362/4885CCR2 3932/4885HTR2C 2353/4885 |
| US-20100105659-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | SLC22A12 1726/4885CCR2 4290/4885HTR2C 2546/4885 |
| US-20150057448-A1 | INTERMEDIATES FOR THE PREPARATION OF PYRIDIN-2-YL-AMINO-1,2,4-THIADIAZOLE DERIVATIVES | PDXK, IL4I1, CDK2 | SLC22A12 4656/4885CCR2 3178/4885HTR2C 238/4885 |
| US-20100204240-A1 | Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus | PDXK, GCKR, GCK | SLC22A12 3450/4885CCR2 3965/4885HTR2C 2425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.